Navigation Links
AssureRx Health Launches Personalized Medicine Test for ADHD

MASON, Ohio, May 7, 2012 /PRNewswire/ -- AssureRx Health, Inc. today announced it has launched a personalized medicine test for the growing number of children and adults diagnosed with attention deficit hyperactivity disorder (ADHD). The new pharmacogenomic test can assist clinicians with important medication decisions that result from genomic differences in how individual patients tolerate ADHD medications.

GeneSightRx ADHD analyzes variations in three genes that influence how a patient might metabolize certain medications used to treat ADHD in children and adults.  Understanding a patient's unique genomic profile may help a clinician individualize a patient's medication selection and avoid side effects that often occur with these medications. The test provides objective, evidence-based information for clinicians to personalize medication selection for each patient.

The GeneSightRx ADHD analysis is based on pharmacogenomics, FDA-approved manufacturer's drug labels, published peer reviewed research, and proven pharmacology. The new ADHD test adds to the company's treatment decision support products that include GeneSightRx Psychotropic, a psychiatric pharmacogenomic product that tests important genomic variants affecting metabolism to psychiatric medications for individual patients. 

ADHD diagnoses increased 66 percent from 6.2 million in 2000 to 10.4 million in 2010, according to a study published in the March/April 2012 issue of Academic Pediatrics. ADHD is the most common childhood disorder and can continue into adulthood. Symptoms of ADHD include an inability to stay focused or pay attention, difficulty controlling behavior, and hyperactivity.

"ADHD is a neurobehavioral disorder affecting millions of children and adults. With the introduction of GeneSightRx ADHD, clinicians now have an objective, evidence-based tool for individualizing ADHD medications," said James S. Burns, president and CEO of AssureRx Health. "Our goal is to build a portfolio of innovative pharmacogenomic and other treatment decision support products to help physicians individualize the treatment of patients with neuropsychiatric and other disorders."

When a clinician orders the test, a DNA sample is taken from the patient with a simple, non-invasive cheek swab.  The specimen is sent overnight to AssureRx Health's CLIA-certified and CAP-accredited laboratory. The ordering clinician receives the patient report via a secure online portal that presents the patient's genomic information in an easy-to-read and clinically actionable format.

About GeneSightRx

GeneSightRx is a laboratory developed genomic test that uses cutting edge technology to measure and analyze clinically important genomic variants in the treatment of psychiatric disorders. The results of the GeneSightRx report can help a clinician understand the way a patient's unique genomic makeup may affect certain psychiatric drugs. The analysis is based on pharmacogenomics, the study of genomic factors that influence an individual's response to drug treatments, FDA approved manufacturer's drug labels, peer-reviewed scientific and clinical publications, and proven drug pharmacology. Quick turnaround time, combined with a customized report of the patient's genomic makeup, clinical experience, and other factors can help a physician make personalized drug treatment choices for each individual patient. To learn more about pharmacogenomics and GeneSightRx, please click here. Be sure to watch the educational video on our YouTube channel.

About AssureRx Health

AssureRx Health, Inc. is a personalized medicine company that specializes in pharmacogenomics dedicated to helping clinicians determine the right drug for individual patients suffering from neuropsychiatric and other disorders. The GeneSightRx analysis is based on pharmacogenomics the study of the genomic factors that influence an individual's response to drug treatments, using FDA approved manufacturers' drug labels, scientific and clinical peer-reviewed publications, and proven pharmacology. The company was founded to commercialize industry-leading personalized medicine technology. To learn more about pharmacogenomics and GeneSightRx, visit

Troy May
Marketing Communications Manager
AssureRx Health Inc.
513-234-0510 Office


SOURCE AssureRx Health, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Medco Research Institute® and AssureRx Health Initiate Pilot Program to Evaluate Adoption and Clinical Impact of Pharmacogenetic Testing for Selection of Psychotropic Medications
2. AssureRx Health Raises $11 Million Series B Financing
3. AssureRx Expands GeneSightRx® Pharmacogenetic Profile with Sixth Gene to Enhance Guidance of Psychiatric Drug Prescribing
4. AssureRx Appoints Senior Executives in Key Roles to Drive Company Growth
5. Seventeen Banner Health facilities achieve final stage of electronic medical record adoption
6. Watson to Present at the Bank of America Merrill Lynch 2012 Health Care Conference
7. Aperture Health, Inc. focuses in on IV Therapy Value Creation and the Merger and Acquisition Activities in the Home Infusion Therapy Sector.
8. Savient Pharmaceuticals to Present at the Bank of America Merrill Lynch 2012 Health Care Conference
9. Bayer Employees Named Rising Stars by Healthcare Businesswomens Association
10. Hill-Rom to Participate in the Bank of America Merrill Lynch 2012 Health Care Conference
11. Optimer Pharmaceuticals to Present at the Bank of America Merrill Lynch 2012 Health Care Conference
Post Your Comments:
(Date:6/24/2016)... , June 24, 2016  Consumers have taken ... regulators/payers have placed more emphasis on patient outcomes. ... support programs in the pharmaceutical industry have evolved ... Consequently, pharmaceutical companies are focusing on becoming more ... providing products and services that improve health. ...
(Date:6/24/2016)... SOUTH SAN FRANCISCO, Calif. , June 24, ... GBT ), a biopharmaceutical company developing novel ... with significant unmet needs, today announced the closing ... 6,400,000 shares of common stock, at the public ... the shares in the offering were offered by ...
(Date:6/24/2016)... 24, 2016 ... the addition of the " Global Markets for ... This report focuses on ... updated review, including its applications in various applications. The ... which includes three main industries: pharmaceutical and biotechnology, food ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... ... Austin residents seeking Mohs surgery services, can now turn to Dr. Jessica ... Peckham for medical and surgical dermatology. , Dr. Dorsey brings specialization to include Mohs ... Mohs Micrographic Surgery completed by Dr. Dorsey was under the direction of Glenn Goldstein, ...
(Date:6/25/2016)... , ... June 25, 2016 , ... ... and non-athletes recover from injury. Recently, he has implemented orthobiologic procedures as a ... area —Johnson is one of the first doctors to perform the treatment. Orthobiologics ...
(Date:6/24/2016)... ... ... June 19, 2016 is World Sickle Cell Observance Day. In an effort to ... treatments, Serenity Recovery Center of Marne, Michigan, has issued a pain management ... (SCD) is a disorder of the red blood cells, which can cause episodes of ...
(Date:6/24/2016)... ... ... Comfort Keepers® of San Diego, CA is excited to announce they are ... drive cancer patients to and from their cancer treatments. Comfort Keepers provides quality ... and ongoing independence. Getting to and from medical treatments is one of the ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... client, The Grove Investment Group (TGIG), has initiated cultivation and processing operations at ... Las Vegas and Pahrump, Nevada. , Puradigm is the manufacturer of a complete ...
Breaking Medicine News(10 mins):